Prime Medicine
IPO
Delivering on the promise of Prime Editing
- Headquarters
- Cambridge, Massachusetts
- Employees
- 201–500
- Founded
- 2019
- Business Model
- B2B
- Website
- primemedicine.com
- Total Funding
- $339.0M
- Last Round
- $24.0M GrantJul 2025
About
Prime Medicine develops next-generation gene therapies using its proprietary Prime Editing platform, which can search and replace disease-causing genetic sequences without causing double-strand DNA breaks. Founded in 2019 based on technology from the Broad Institute, the company focuses on liver, lung, immunology, and oncology indications. It has a strategic collaboration with Bristol Myers Squibb and is advancing programs toward IND filings.
Sign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Create Free AccountFunding History
Sign up to view funding details
Create a free account to see full funding history, valuations, and investor participation.
Create Free Account